The Pα Take
At times, our coverage can be lengthy. Our quick-look summaries and analysis provide key takeaways, opinions and analysis throughout our content.
An insider’s guide to the business, policy and science of psychedelics.
Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and culture. ∎
Pα+ is read by the world’s leading drug developers, investors, and practitioners, including:
Quick Subscribe:
Ready to subscribe to Pα+? Choose a monthly or annual plan by clicking the appropriate button below. (If you’re looking for team/group plans, or to learn more, keep reading.)
Our Plans
Pα+
Pα+ subscribers receive regular Bulletins, articles, interviews with insiders and quick-take analysis of major stories and developments (e.g., significant trial results, financing rounds, policy reforms, etc.); along with access to our back catalogue and Library.
- Regular Bulletins covering key topics and trends in the psychedelics space
- Regular articles and deep dives across psychedelic research, policy and business
- Interviews with insiders
- Monthly interactive database and commentary on psychedelic patents
- Quick-take analysis of major developments
- Access to our Library of primers and explainers
Subscribe annually or monthly:
Note: These subscriptions are for personal use only. Should you wish to explore team pricing, please see below.
Group, Team & Corporate Plans
Group, Team and Corporate pricing plans are available, please complete the form below or get in touch via email to learn more.
Aside from group pricing, we also offer a higher-tier subscription that provides additional tracking options: e.g., updates on specific companies, compounds or indications. If you’re looking for more support, project-specific advice, consultancy, or anything more ‘involved’, please see our Advisory offering or get in touch with Josh to discuss further.
Free
Free Psychedelic Alpha subscribers receive a weekly round-up of news on psychedelics, as well as the occasional article.
- Weekly Psychedelic News Feed
- Occasional Articles
Enter your email below to join our Free list:
Our Approach
We adopt a critical, analytical point of view—not pessimistic or cynical—that we hope provides a unique lens on the psychedelic industry for years to come: an opinionated exploration of the intersection between psychedelics and business. We don’t shy away from difficult questions and dive head-first into complexity.
Pα+ provides a one-stop solution for staying abreast of this rapidly developing space, with deeply researched deep dives and ‘in the weeds’ analysis complemented by our quick-takes, in-line explainers and backgrounders.
Our core coverage is the business of psychedelics, but this revolves around drug development, financing, science and drug development, legal and cultural developments, and so on.
Here are a handful of previews of our Pα+ coverage from the past year or so:
- Day 1 Dispatch from ‘Advancing Psychedelic Clinical Study Design’, Hosted by the Reagan-Udall Foundation for the FDA
- Gilgamesh Scoops $14m from NIDA to Develop Safer Ibogaine Analog for Opioid Use Disorder
- Compass Pathways CEO Kabir Nath Discusses Commercialisation, ‘Psychological Support’ and Competitive Landscape
- Bulletin #150: Drug Development and Research Updates
Should you wish to review samples of our Pα+ content, please get in touch.
We also strive to actively build community among our subscribers, and correspondence is encouraged. ∎
Deeply Researched
Whether based on in-house data, interviews or outside information and research, we cite our sources and provide further reading.
Explainers & Context
It can be hard to stay abreast of every development within and beyond the psychedelics space. We strive to include in-line backgrounders and primers where relevant.
Types of Coverage
Regular Psychedelic Bulletins
Our regular Bulletins summarise and analyse key developments from recent weeks. With over three years of reporting under our belt, we’re well-placed to tune out the noise.
Deep Dives and Features
We regularly pen a variety of features and deep dives: from backgrounders and explainer articles through to special reports on specific companies, developments or themes.
and more...
- Annotated insider interviews
- Business case studies and financials
- Quick-take analysis on significant stories, announcements and developments
- Ask Me Anything with Psychedelic Alpha’s team and network
Monthly Psychedelic Patent Analysis
- Headline figures regarding published psychedelic patent applications and grants.
- An interactive database of the month’s grants, allowances, abandonments, rejections and responses filed.
- Commentary on a select handful of patent-related actions.
Why Psychedelic Alpha?
We have been reporting on the psychedelics industry for over three years with regular Bulletins, deep dives and analysis as well as unique datasets and resources. In this time our founder and editor, Josh Hardman, has presented at conferences including SXSW, Psychedelic Science and Horizons.
We’re lucky to be informed by a network of experts and advisors: from lawyers and patent attorneys through to neuropsychopharmacologists and VCs.
Psychedelic Alpha is trusted by over ten thousand readers as well as top-tier mainstream media publications, regulatory and governmental bodies, and hundreds of companies. ∎
Who Reads Pα+?
